January 22, 2020

Scientists isolate biomarkers that can identify delirium risk and severity

Dr. Khan quote on delirium biomarkers

Opens door to easy, early identification of individuals at risk for delirium complications

Regenstrief Institute and Indiana University School of Medicine researchers have identified blood-based biomarkers associated with both delirium duration and severity in critically ill patients. This finding opens the door to easy, early identification of individuals at risk for longer delirium duration and higher delirium severity and could potentially lead to new treatments of this brain failure for which drugs have been shown to be largely ineffective.

An estimated 7 million hospitalized Americans suffer from the acute confusion and disorientation, characteristics of delirium, including a majority of patients in medical or surgical intensive care units (ICUs). Individuals who experience delirium in the ICU are more likely to have more hospital-associated complications, longer stays and higher risk of readmission. They are more likely to experience cognitive impairment and also have a greater likelihood of dying for up to a year after their hospital stay than ICU patients who did not experience delirium.

“If you can tell which patients will have higher delirium severity and longer duration and therefore greater probability of death, there are important treatment implications,” said Regenstrief Institute research scientist and IU School of Medicine faculty member Babar Khan, M.D., who led the research and is the president of the American Delirium Society. “Analyzing biomarkers to stratify risk for delirium is a promising approach with the potential to be applied regularly in ICU patients in the near future.”

In a new observational study, Dr. Khan and colleagues report that biomarkers for astrocyte and glial activation as well as for inflammation were associated with increased delirium duration and severity and greater in-hospital mortality.

Biomarkers of the 321 study participants, all of whom experienced delirium in an ICU, were identified from samples obtained via simple blood draws. Delirium severity was determined using a tool developed by a team including Regenstrief, IU School of Medicine and Purdue College of Pharmacy scientists. The CAM-ICU-7, short for Confusion Assessment Method for the Intensive Care Unit 7 — is easy to administer, even to patients on mechanical ventilators. More than half of ICU patients in the U.S. receive mechanical ventilation.

Each day with delirium in the ICU is associated with a 10 percent increased likelihood of death, according to Dr. Khan, so diminishing its duration and ultimately preventing it is critical. Regenstrief, IU School of Medicine and research scientists from other institutions have conclusively shown in several large trials that antipsychotics, such as the widely used haloperidol, are not effective for the management of delirium duration or severity.

Regenstrief and IU School of Medicine researchers are actively exploring other approaches to delirium. Dr. Khan is co-principal investigator of an ongoing study that is the first to test whether listening to music, a non-pharmacological strategy that has been shown to decrease over-sedation, anxiety and stress in critically ill patients — all factors that predispose to ICU delirium – and lowers the likelihood of developing delirium. In a completed study, Regenstrief researchers determined that waking ICU patients and having them breathe on their own decreased acute brain failure.

The new study, “Biomarkers of Delirium Duration and Delirium Severity in the ICU” has been published online ahead of print in the journal Critical Care Medicine.

Authors in addition to Dr. Babar Khan are:

  • Regenstrief Institute research scientists and IU School of Medicine faculty Sikandar H. Khan, D.O., M.S., and Malaz Boustani, M.D., MPH.
  • Regenstrief Institute research scientist and Purdue University College of Pharmacy faculty Noll Campbell, PharmD, M.S.
  • Anthony J. Perkins, M.S., IU Center for Health Innovation and Implementation Science and Indiana CTSI.
  • Nagendra K. Prasad, BVSc, PhD, MBA; Anantha Shekhar, M.D., PhD; Sujuan Gao, PhD; Sophia Wang, M.D. and Homer L. Twigg III, M.D., all of the IU School of Medicine. Dr. Shekhar is also the founding director of the Indiana Clinical and Translational Sciences Institute.
  • Edward R. Marcantonio, M.D., S.M., of Beth Israel Deaconess Medical Center and Harvard Medical School.

The study was supported by National Institute on Aging (NIA) grant K23AG043476. The NIA is part of the National Institutes of Health.

About Regenstrief Institute

Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. The Regenstrief Institute and its researchers are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

A key research partner to Indiana University, Regenstrief Institute is celebrating 50 years of healthcare innovation. Sam Regenstrief, a successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.

About Indiana University School of Medicine

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

About Babar Khan, M.D.

In addition to his appointment as a Regenstrief Institute research scientist, Babar Khan, M.D., is associate director at Indiana University Center for Aging Research at Regenstrief Institute and associate professor of medicine at IU School of Medicine. He is the president of the American Delirium Society.

Related News

Aaron Carroll, M.D.

Call for Papers on Artificial Intelligence Applied to Pediatric Care

Published in JAMA Pediatrics. Here is a link to the article. Regenstrief Institute author: Aaron E. Carroll, M.D., M.S.

Critical gap in colorectal cancer screening process: follow-up after positive stool test

INDIANAPOLIS – Screening for colorectal cancer presents a unique opportunity unavailable for most other types of cancers. Screening allows

Eric Vachon, PhD, RN

Study explores how relationship with partner impacts breast cancer survivor’s emotional and physical well-being

Satisfaction with relationship and better agreement are linked with positive health outcomes Diagnosis and treatment of breast cancer places